Abbott tests the power of a Big Pharma name with international branding push

Abbott Laboratories ($ABT) is already one of the biggest drugmakers in emerging markets. But with growing competition there from Big Pharma and plenty of smaller companies, Abbott wants to make sure its products stay in the forefront. So, it's rolling out a new branding campaign to cozy up with consumers and amp up its international name recognition. Report

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.